Report overview
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
This report contains market size and forecasts of Neuroblastoma Chemotherapy Drugs in global, including the following market information:
Global Neuroblastoma Chemotherapy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Neuroblastoma Chemotherapy Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Neuroblastoma Chemotherapy Drugs companies in 2021 (%)
The global Neuroblastoma Chemotherapy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cyclophosphamide Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuroblastoma Chemotherapy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuroblastoma Chemotherapy Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, by Type, 2021 (%)
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Global Neuroblastoma Chemotherapy Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Other
Global Neuroblastoma Chemotherapy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Chemotherapy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuroblastoma Chemotherapy Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Neuroblastoma Chemotherapy Drugs revenues share in global market, 2021 (%)
Key companies Neuroblastoma Chemotherapy Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Neuroblastoma Chemotherapy Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
